Neil  Solomons net worth and biography

Neil Solomons Biography and Net Worth

Neil Solomons co-founded privately held Aurinia Pharmaceuticals in 2012. He is a seasoned pharmaceutical physician with 18 years of clinical development and medical affairs experience in both large pharma and biotech. He is a recognized expert in rare disease drug development and is widely published in this field. Neil joined Aurinia from Vifor Pharma, formerly Aspreva Pharmaceuticals (NASDAQ: ASPV) where he held the position of Vice President, Research and Development, being the lead clinician in the development of CellCept® in rare diseases. Neil led the CellCept clinical development teams of over 50 people that saw the completion, reporting, and publication of studies in pemphigus vulgaris and myasthenia gravis (both industry firsts), and the successful landmark lupus nephritis study called the Aspreva Lupus Management Study (ALMS). He was responsible for all clinical development activities from Phases 1 to 3, as well as participated in the formulation of R&D strategy, portfolio management, and due diligence efforts. Prior to Vifor and Aspreva, Neil held a variety of positions at Roche in both global clinical development and medical affairs in transplantation, virology, and auto-immune diseases. While at Roche, Neil led a diverse team in the development and implementation of post-marketing studies with a budget exceeding $15 million for its transplantation (CellCept® and Zenapax®) and virology (Cytovene®) franchises. 

Neil qualified in medicine in 1991 receiving his MBBS (M.D.) at Guys Hospital Medical School, London. He subsequently worked as a physician in London UK, completing specialist training in anesthesia and intensive care. His research interests included sepsis and chronic pain.

What is Neil Solomons' net worth?

The estimated net worth of Neil Solomons is at least $786,495.00 as of November 10th, 2021. Dr. Solomons owns 157,299 shares of Aurinia Pharmaceuticals stock worth more than $786,495 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Solomons may own. Learn More about Neil Solomons' net worth.

How do I contact Neil Solomons?

The corporate mailing address for Dr. Solomons and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at [email protected]. Learn More on Neil Solomons' contact information.

Has Neil Solomons been buying or selling shares of Aurinia Pharmaceuticals?

Neil Solomons has not been actively trading shares of Aurinia Pharmaceuticals during the past quarter. Most recently, Neil Solomons sold 45,000 shares of the business's stock in a transaction on Monday, November 1st. The shares were sold at an average price of $31.64, for a transaction totalling $1,423,800.00. Learn More on Neil Solomons' trading history.

Who are Aurinia Pharmaceuticals' active insiders?

Aurinia Pharmaceuticals' insider roster includes Matthew Donley (VP), Peter Greenleaf (CEO), Robert Huizinga (EVP), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider). Learn More on Aurinia Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Aurinia Pharmaceuticals?

In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 9,005 shares worth more than $101,211.34. The most recent insider tranaction occured on May, 23rd when Director David R.W. Jayne sold 8,733 shares worth more than $98,333.58. Insiders at Aurinia Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.

Information on this page was last updated on 5/23/2023.

Neil Solomons Insider Trading History at Aurinia Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2021Sell45,000$31.64$1,423,800.00View SEC Filing Icon  
8/25/2021Sell5,000$15.85$79,250.00137,299View SEC Filing Icon  
See Full Table

Neil Solomons Buying and Selling Activity at Aurinia Pharmaceuticals

This chart shows Neil Solomons's buying and selling at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Read More

Today's Range

Now: $5.00
Low: $4.85
High: $5.02

50 Day Range

MA: $6.45
Low: $4.93
High: $8.32

2 Week Range

Now: $5.00
Low: $4.85
High: $12.43

Volume

1,437,027 shs

Average Volume

1,647,794 shs

Market Capitalization

$723.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37